agar/neoplasms

BACKGROUND The genetic basis of cancer dissemination, also known as metastasis, has been subject to intense debate. Metastasis genes have been identified as stress response genes, which in cancer are deregulated on the levels of aberrant expression and splicing. Osteopontin is a cytokine that is

BACKGROUND The genetic basis of cancer dissemination, also known as metastasis, has been subject to intense debate. Metastasis genes have been identified as stress response genes, which in cancer are deregulated on the levels of aberrant expression and splicing. Osteopontin is a cytokine that is

The present invention relates to methodology and associated genetic constructs for the suppression of oncogene-mediated, transformation, tumorigenesis and metastasis. In particular, this invention relates to the suppression of oncogenesis that is mediated by the HER-2/c-erb B-2/neu oncogene, an

A. Field of the Invention The present invention relates to methodology and associated genetic constructs for the suppression of oncogene-mediated, transformation, tumorigenesis and metastasis. In particular, this invention relates to the suppression of oncogenesis that is mediated by the HER-2/c-erb

BACKGROUND OF THE INVENTION A. Field of the Invention The present invention relates to methodology and associated genetic constructs for the suppression of oncogene-mediated, transformation, tumorigenesis and metastasis. In particular, this invention relates to the suppression of oncogenesis that is

BACKGROUND OF THE INVENTION A. Field of the Invention The present invention relates to methodology and associated genetic constructs for the suppression of oncogene-mediated, transformation, tumorigenesis and metastasis. In particular, this invention relates to the suppression of oncogenesis that is

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the field of cancer and also to polypeptides with growth-promoting activities. The invention is particularly directed to the identification of growth factors, primarily from bone and prostate tissues,

CROSS-REFERENCE TO RELATED APPLICATION This application is a national stage filing under 35 U.S.C. .sctn.371 of international application PCT/SG2011/000400, filed Nov. 11, 2011, which claims priority to Singapore Application No. 201008288-1, filed Nov. 11, 2010, the contents of all of which are

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to tumors. More specifically, the present invention discloses a method of inhibiting tumor growth and up-regulating transcriptional activity of p53 by utilizing Nucleophosmin/B23-binding peptide. 2. Description of

FIELD OF THE INVENTION This invention pertains generally to products and techniques for testing the resolution capabilities of nuclear magnetic resonance (NMR) imaging equipment and particularly to imaging processes in which hydrogen is the monitored nucleus. BACKGROUND OF THE INVENTION The early

FIELD OF THE INVENTION The present invention relates to genes which encode novel proteins related to a family of receptor proteins typified by two related membrane spanning tyrosinc kinases: the Epidermal Growth Factor receptor (EGFR), which is encoded by the erbB gene, the normal human counterpart

FIELD OF THE INVENTION This invention relates to the epidermal growth factor related proteins, polynucleotides encoding these proteins and methods for using these proteins. The cellular machinery involved in mitogenesis is complex, and not yet fully understood. In general, receptors present on the

FIELD OF THE INVENTION This invention relates to the epidermal growth factor related proteins, polynucleotides encoding these proteins and methods for using these proteins. The cellular machinery involved in mitogenesis is complex, and not yet fully understood. In general, receptors present on the

FIELD OF THE INVENTION 1. Background of the Invention This invention relates to capsules for preparations for oral administration and also to capsule preparations for oral administration using said capsules. More particularly, this invention relates to capsules being able to be administered orally

TECHNICAL FIELD OF THE INVENTION This invention is related to the field of cancer diagnostics and therapeutics. BACKGROUND OF THE INVENTION p53 is the most commonly inactivated gene in human cancer and loss of critical p53 pathways are central to tumorigenesis.sup.1,2. The p53 protein binds specific